Shinichi Matsumoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shinichi Matsumoto has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Morihito Takita
Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1247, Japan
14 shared publications Daisuke Chujo
Pancreatic Islet Transplantation Project, Research Institute National Center for Global Health and Medicine Tokyo Japan
11 shared publicationsMasayuki Shimoda
Islet Transplantation Project, National Institute for Global Health and Medicine, Tokyo, Japan
10 shared publications- Hirofumi Noguchi
Department of Regenerative Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan
9 shared publications Marlon F. Levy
Annette C. and Harold C. Simmons Transplant Institute, Dallas, TX 75246
8 shared publications- Bashoo Naziruddin
Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX
7 shared publications
Latest Publications
- Open Access
Editorial for Special Issue “Islet Transplantation”
Islet cell transplantation is revolutionary
Open AccessEditorial for Special Issue “Islet Transplantation”
Islet cell transplantation is revolutionary
- Open Access
- 18 April 2025
- Published by SAGE Publications in Cell Transplantation
- Vol. 34
Donor pigs for clinical islet xenotransplantation: Review and future directions
Allogeneic islet transplantation becomes a viable option for patients with unstable type 1 diabetes. However, considering the huge number of patients with type 1 diabetes, human donor shortage is a serious issue. To overcome the donor shortage issue, xenotransplantation is an attractive option. In fact, clinical islet xenotransplantation has been conducted since 1990s. The first clinical trial was performed using fetal pigs and demonstrated the porcine pancreatic tissue could survive in human body with immunosuppressive strategies. To scale up the islet production, Canadian group established a method for islet isolation from neonatal pigs. Their method has been used for clinical islet xenotransplantation in New Zealand, Russian, Mexico, Argentina, and China. Recently Korean group published a clinical protocol for islet xenotransplantation using adult pigs. For the next generation of islet xenotransplantation, gene-modified pigs were created. Especially “superislets” created by Belgian group demonstrated promising preclinical outcomes. With advanced donor pigs, islet xenotransplantation might become a suitable treatment for the majority of type 1 diabetic patients.
- 18 April 2025
- Published by SAGE Publications in Cell Transplantation
- Vol. 34
Open AccessDonor pigs for clinical islet xenotransplantation: Review and future directions
Allogeneic islet transplantation becomes a viable option for patients with unstable type 1 diabetes. However, considering the huge number of patients with type 1 diabetes, human donor shortage is a serious issue. To overcome the donor shortage issue, xenotransplantation is an attractive option. In fact, clinical islet xenotransplantation has been conducted since 1990s. The first clinical trial was performed using fetal pigs and demonstrated the porcine pancreatic tissue could survive in human body with immunosuppressive strategies. To scale up the islet production, Canadian group established a method for islet isolation from neonatal pigs. Their method has been used for clinical islet xenotransplantation in New Zealand, Russian, Mexico, Argentina, and China. Recently Korean group published a clinical protocol for islet xenotransplantation using adult pigs. For the next generation of islet xenotransplantation, gene-modified pigs were created. Especially “superislets” created by Belgian group demonstrated promising preclinical outcomes. With advanced donor pigs, islet xenotransplantation might become a suitable treatment for the majority of type 1 diabetic patients.
- Open Access
Clinical Islet Xenotransplantation: Development of Isolation Protocol, Anti-Rejection Strategies, and Clinical Outcomes
Allogeneic islet transplantation has become a standard therapy for unstable type 1 diabetes. However, considering the large number of type 1 diabetic patients, the shortage of donors is a serious issue. To address this issue, clinical islet xenotransplantation is conducted. The first clinical islet xenotransplantation was performed by a Swedish team using fetal pancreatic tissue. Thereafter, clinical trials of islet xenotransplantation were conducted in New Zealand, Russia, Mexico, Argentina, and China using neonatal pig islets. In clinical trials, fetal or neonatal pancreata are used because of the established reliable islet isolation methods. These trials demonstrate the method’s safety and efficacy. Currently, the limited number of source animal facilities is a problem in terms of promoting islet xenotransplantation. This limitation is due to the high cost of source animal facilities and the uncertain future of xenotransplantation. In the United States, the first xenogeneic heart transplantation has been performed, which could promote xenotransplantation. In Japan, to enhance xenotransplantation, the ‘Medical Porcine Development Association’ has been established. We hope that xenogeneic transplantation will become a clinical reality, serving to address the shortage of donors.
Open AccessClinical Islet Xenotransplantation: Development of Isolation Protocol, Anti-Rejection Strategies, and Clinical Outcomes
Allogeneic islet transplantation has become a standard therapy for unstable type 1 diabetes. However, considering the large number of type 1 diabetic patients, the shortage of donors is a serious issue. To address this issue, clinical islet xenotransplantation is conducted. The first clinical islet xenotransplantation was performed by a Swedish team using fetal pancreatic tissue. Thereafter, clinical trials of islet xenotransplantation were conducted in New Zealand, Russia, Mexico, Argentina, and China using neonatal pig islets. In clinical trials, fetal or neonatal pancreata are used because of the established reliable islet isolation methods. These trials demonstrate the method’s safety and efficacy. Currently, the limited number of source animal facilities is a problem in terms of promoting islet xenotransplantation. This limitation is due to the high cost of source animal facilities and the uncertain future of xenotransplantation. In the United States, the first xenogeneic heart transplantation has been performed, which could promote xenotransplantation. In Japan, to enhance xenotransplantation, the ‘Medical Porcine Development Association’ has been established. We hope that xenogeneic transplantation will become a clinical reality, serving to address the shortage of donors.
- Open Access
- 5 December 2023
- Published by IntechOpen
Allogeneic Islet Transplantation and Future
Pancreatic islets contain beta cells which produce insulin based on the blood glucose levels resulting in tight control of blood glucose levels. In type 1 diabetic patients, most of the beta cells are destroyed, therefore, pharmaceutical insulin injection is mandatory to avoid diabetes-related illness and death. Even with recent advanced insulin therapy, hypoglycemia is a critical limiting factor to control blood glucose levels. There is no doubt that hypoglycemia can be fatal. Allogeneic islet transplantation can prevent severe hypoglycemia and provide excellent blood glucose control. On the other hand, allograft donor shortage is the major issue. To overcome donor shortage, xenograft has been used and shown safety and efficacy. Recently stem-cell-derived beta cells are clinically applied. In this chapter, the history and current status of allogenic islet transplantation and future scope are described.
- 5 December 2023
- Published by IntechOpen
Open AccessAllogeneic Islet Transplantation and Future
Pancreatic islets contain beta cells which produce insulin based on the blood glucose levels resulting in tight control of blood glucose levels. In type 1 diabetic patients, most of the beta cells are destroyed, therefore, pharmaceutical insulin injection is mandatory to avoid diabetes-related illness and death. Even with recent advanced insulin therapy, hypoglycemia is a critical limiting factor to control blood glucose levels. There is no doubt that hypoglycemia can be fatal. Allogeneic islet transplantation can prevent severe hypoglycemia and provide excellent blood glucose control. On the other hand, allograft donor shortage is the major issue. To overcome donor shortage, xenograft has been used and shown safety and efficacy. Recently stem-cell-derived beta cells are clinically applied. In this chapter, the history and current status of allogenic islet transplantation and future scope are described.
- Open Access
- 17 October 2023
- Published by Wiley in Xenotransplantation
- Vol. 31 (1) , e12831
Development and characterization of islet‐derived mesenchymal stem cells from clinical grade neonatal porcine cryopreserved islets
Background: Porcine tissues display a great potential as donor tissues in xenotransplantation, including cell therapy. Cryopreserving clinical grade porcine tissue and using it as a source for establishing therapeutic cells should be advantageous for transportation and scheduled manufacturing of MSCs. Of note, we previously performed encapsulated porcine islet transplantation for the treatment of unstable type 1 diabetes mellitus in the clinical setting. It has been reported that co‐transplantation of islets and Mesenchymal stem cells (MSCs) enhanced efficacy. We assume that co‐transplantation of porcine islets and porcine islet‐derived MSCs could improve the efficacy of clinical islet xenotransplantation.Methods: MSCs were established from fresh and cryopreserved non‐clinical grade neonatal porcine islets and bone marrow (termed non‐clinical grade npISLET‐MSCs and npBM‐MSCs, respectively), as well as from cryopreserved clinical grade neonatal porcine islets (termed clinical grade npISLET‐MSCs). Subsequently, the cell proliferation rate and diameter, surface marker expression, adipogenesis, osteogenesis, and colony‐forming efficiency of the MSCs were assessed.Results: Cell proliferation rate and diameter did not differ between clinical grade and non‐clinical grade npISLET‐MSCs. However, non‐clinical grade npBM‐MSCs were significantly shorter and smaller than both npISLET‐MSCs (p < 0.05). MSC markers (CD29, CD44, and CD90) were strongly expressed in clinical grade npISLET‐MSCs and non‐clinical grade npISLET‐MSCs and npBM‐MSCs. The expression of MSC‐negative markers CD31, CD34, and SLA‐DR was low in all MSCs. Clinical grade npISLET‐MSCs derived from adipose and osteoid tissues were positive for Oil Red and alkaline phosphatase staining. The results of colony‐forming assay were not significantly different between clinical grade npISLET‐MSCs and non‐clinical grade npBM‐MSCs.Conclusion: The method described herein was successful in of developing clinical grade npISLET‐MSCs from cryopreserved islets. Cryopreserved clinical grade porcine islets could be an excellent stable source of MSCs for cell therapy.
- 17 October 2023
- Published by Wiley in Xenotransplantation
- Vol. 31 (1) , e12831
Open AccessDevelopment and characterization of islet‐derived mesenchymal stem cells from clinical grade neonatal porcine cryopreserved islets
Background: Porcine tissues display a great potential as donor tissues in xenotransplantation, including cell therapy. Cryopreserving clinical grade porcine tissue and using it as a source for establishing therapeutic cells should be advantageous for transportation and scheduled manufacturing of MSCs. Of note, we previously performed encapsulated porcine islet transplantation for the treatment of unstable type 1 diabetes mellitus in the clinical setting. It has been reported that co‐transplantation of islets and Mesenchymal stem cells (MSCs) enhanced efficacy. We assume that co‐transplantation of porcine islets and porcine islet‐derived MSCs could improve the efficacy of clinical islet xenotransplantation.Methods: MSCs were established from fresh and cryopreserved non‐clinical grade neonatal porcine islets and bone marrow (termed non‐clinical grade npISLET‐MSCs and npBM‐MSCs, respectively), as well as from cryopreserved clinical grade neonatal porcine islets (termed clinical grade npISLET‐MSCs). Subsequently, the cell proliferation rate and diameter, surface marker expression, adipogenesis, osteogenesis, and colony‐forming efficiency of the MSCs were assessed.Results: Cell proliferation rate and diameter did not differ between clinical grade and non‐clinical grade npISLET‐MSCs. However, non‐clinical grade npBM‐MSCs were significantly shorter and smaller than both npISLET‐MSCs (p < 0.05). MSC markers (CD29, CD44, and CD90) were strongly expressed in clinical grade npISLET‐MSCs and non‐clinical grade npISLET‐MSCs and npBM‐MSCs. The expression of MSC‐negative markers CD31, CD34, and SLA‐DR was low in all MSCs. Clinical grade npISLET‐MSCs derived from adipose and osteoid tissues were positive for Oil Red and alkaline phosphatase staining. The results of colony‐forming assay were not significantly different between clinical grade npISLET‐MSCs and non‐clinical grade npBM‐MSCs.Conclusion: The method described herein was successful in of developing clinical grade npISLET‐MSCs from cryopreserved islets. Cryopreserved clinical grade porcine islets could be an excellent stable source of MSCs for cell therapy.
- Open Access
- 8 August 2023
- Published by Wiley in Medicine Advances
- Vol. 1 (3) , 210-218
Acceptance of encapsulated porcine islet xenotransplantation by patients and doctors in the US
Introduction: Previously, we performed encapsulated porcine islet xenotransplantation for the treatment of unstable type 1 diabetic patients and demonstrated the clinical benefit and safety in New Zealand and Argentina. Conversely, the treatment of type 1 diabetes differs from country to country; therefore, understanding the acceptance of the new treatment by patients and medical doctors in each country is important. In this study, a survey study of the acceptance of the encapsulated porcine islet xenotransplantation by the type 1 diabetic patients and medical doctors in the US was conducted.Methods: The questionnaires consisted of the acceptance of the encapsulated porcine islet xenotransplantation without immunosuppression, and the reasons for selecting and not selecting. Moreover, we conducted a sub‐analysis among patient groups regarding severe hypoglycemia and HbA1c levels.Results: The majority of patients and doctors (patients, 63.8%; doctors, 70.0%) had a positive opinion to accept this treatment. A significantly high number of doctors selected no immunosuppression for selecting this treatment (patients, 35.5%; doctors, 53.6%; p < 0.001), and a significantly high number of patients selected not insulin free for not selecting this treatment (patients 20.4%, doctors 12.4%, p < 0.05). The high HbA1c group had the highest ‘definitely’ accept rate, which was significantly higher than those of the other HbA1c groups (High HbA1c group, 50.0%; other HbA1c groups, 22.2%; p < 0.05).Conclusion: In conclusion, the majority of US patients and doctors had positive opinions to accept the encapsulated porcine islet xenotransplantation. Type 1 diabetic patients with high HbA1c levels had the highest ‘definitely’ acceptance rates.
- 8 August 2023
- Published by Wiley in Medicine Advances
- Vol. 1 (3) , 210-218
Open AccessAcceptance of encapsulated porcine islet xenotransplantation by patients and doctors in the US
Introduction: Previously, we performed encapsulated porcine islet xenotransplantation for the treatment of unstable type 1 diabetic patients and demonstrated the clinical benefit and safety in New Zealand and Argentina. Conversely, the treatment of type 1 diabetes differs from country to country; therefore, understanding the acceptance of the new treatment by patients and medical doctors in each country is important. In this study, a survey study of the acceptance of the encapsulated porcine islet xenotransplantation by the type 1 diabetic patients and medical doctors in the US was conducted.Methods: The questionnaires consisted of the acceptance of the encapsulated porcine islet xenotransplantation without immunosuppression, and the reasons for selecting and not selecting. Moreover, we conducted a sub‐analysis among patient groups regarding severe hypoglycemia and HbA1c levels.Results: The majority of patients and doctors (patients, 63.8%; doctors, 70.0%) had a positive opinion to accept this treatment. A significantly high number of doctors selected no immunosuppression for selecting this treatment (patients, 35.5%; doctors, 53.6%; p < 0.001), and a significantly high number of patients selected not insulin free for not selecting this treatment (patients 20.4%, doctors 12.4%, p < 0.05). The high HbA1c group had the highest ‘definitely’ accept rate, which was significantly higher than those of the other HbA1c groups (High HbA1c group, 50.0%; other HbA1c groups, 22.2%; p < 0.05).Conclusion: In conclusion, the majority of US patients and doctors had positive opinions to accept the encapsulated porcine islet xenotransplantation. Type 1 diabetic patients with high HbA1c levels had the highest ‘definitely’ acceptance rates.
- Open Access
- 4 April 2023
- Published by Wiley in Xenotransplantation
- Vol. 30 (3)
Patients’ opinions 10 years after receiving encapsulated porcine islet xenotransplantation without immunosuppression
Background: Previously we performed clinical encapsulated neonatal porcine islet transplantation under comprehensive regulation, and demonstrated the efficacy and safety. To analyze the patients’ quality of life (QOL), we assessed patients’ opinions 10 years after islet xenotransplantation.Methods: Twenty‐one type 1 diabetic patients received microencapsulated neonatal porcine islet transplants in Argentina were enrolled. Seven patients were enrolled in efficacy and safety study and 14 patients were enrolled in safety studies. Patients’ opinions related to the current and pre‐transplant status of diabetes control, blood glucose levels, severe hypoglycemia, and hyperglycemia required hospitalization were analyzed. In addition, opinions related to islet xenotransplantation were assessed.Results: At the time of this survey, average HbA1c was still significantly lower compared to pre‐transplantation (8.5 ± 0.9 (%) at pre‐transplant and 7.4 ± 0.5(%) at the survey, p < .05) and average insulin dose were also lower (0.95 ± 0.32 (IU/kg) at pre‐transplant and 0.73 ± 0.27 (IU) at the survey). The majority of patients improved diabetes control (71%), blood glucose levels (76%), severe hypoglycemia (86%) and hyperglycemia required hospitalization (76%), and no patients deteriorated in all of the categories when compared with pre‐transplantation. No patients had cancer, or psychological problem, and one patient had a serious adverse event. The majority of patients wanted to recommend this treatment to other patients (76%) and receive booster transplantation (85.7%).Conclusions: The majority of patients had positive opinions related to the encapsulated porcine islet xenotransplantation 10 years after transplantation.
- 4 April 2023
- Published by Wiley in Xenotransplantation
- Vol. 30 (3)
Open AccessPatients’ opinions 10 years after receiving encapsulated porcine islet xenotransplantation without immunosuppression
Background: Previously we performed clinical encapsulated neonatal porcine islet transplantation under comprehensive regulation, and demonstrated the efficacy and safety. To analyze the patients’ quality of life (QOL), we assessed patients’ opinions 10 years after islet xenotransplantation.Methods: Twenty‐one type 1 diabetic patients received microencapsulated neonatal porcine islet transplants in Argentina were enrolled. Seven patients were enrolled in efficacy and safety study and 14 patients were enrolled in safety studies. Patients’ opinions related to the current and pre‐transplant status of diabetes control, blood glucose levels, severe hypoglycemia, and hyperglycemia required hospitalization were analyzed. In addition, opinions related to islet xenotransplantation were assessed.Results: At the time of this survey, average HbA1c was still significantly lower compared to pre‐transplantation (8.5 ± 0.9 (%) at pre‐transplant and 7.4 ± 0.5(%) at the survey, p < .05) and average insulin dose were also lower (0.95 ± 0.32 (IU/kg) at pre‐transplant and 0.73 ± 0.27 (IU) at the survey). The majority of patients improved diabetes control (71%), blood glucose levels (76%), severe hypoglycemia (86%) and hyperglycemia required hospitalization (76%), and no patients deteriorated in all of the categories when compared with pre‐transplantation. No patients had cancer, or psychological problem, and one patient had a serious adverse event. The majority of patients wanted to recommend this treatment to other patients (76%) and receive booster transplantation (85.7%).Conclusions: The majority of patients had positive opinions related to the encapsulated porcine islet xenotransplantation 10 years after transplantation.
- 12 March 2022
- Published by Wiley in Xenotransplantation
- Vol. 29 (2) , e12739
Xenotransplantation of neonatal porcine bone marrow–derived mesenchymal stem cells improves diabetic wound healing by promoting angiogenesis and lymphangiogenesis
Background: Some clinical trials have shown the usefulness of stem cell therapy for diabetic foot ulcers. However, the donor supply is limited, and the process is time consuming and expensive. This study assessed the therapeutic effects of neonatal porcine bone marrow–derived mesenchymal stem cell (npBM‐MSC) xenotransplantation using diabetic wound model mice.Methods: All layers of back skin were removed from streptozotocin‐induced diabetic mice. In the npBM‐MSCs group, npBM‐MSCs were transplanted to the wound, and syngeneic mouse bone marrow–derived mesenchymal stem cells (mBM‐MSCs) were transplanted to the wound in the mBM‐MSCs group. The control group comprised diabetic mice that did not receive cellular therapy. The therapeutic effects of the transplantation were evaluated according to the rate of wound closure and the promotion of neovascularization in the wound.Results: The wound closure rate was significantly improved in the npBM‐MSCs group compared with the control group (p < .001 at postoperative day [POD] 4 and p < .01 at POD 7) and mBM‐MSCs groups (p < .05 at POD 4). Prominent promotion of both angiogenesis and lymphangiogenesis was observed in the npBM‐MSCs group. Furthermore, the expression of murine Prox1 and both porcine and murine Vegfs and Tgfb1 in the wounds was enhanced until POD 4 by npBM‐MSCs transplantation. The amounts of vascular endothelial growth factor (VEGF) A, VEGFC, and transforming growth factor β1 secreted from npBM‐MSCs were higher than those from mBM‐MSCs (p < .05).Conclusion: Xenotransplantation of npBM‐MSCs improved diabetic wound healing by promoting both angiogenesis and lymphangiogenesis.
- 12 March 2022
- Published by Wiley in Xenotransplantation
- Vol. 29 (2) , e12739
Xenotransplantation of neonatal porcine bone marrow–derived mesenchymal stem cells improves diabetic wound healing by promoting angiogenesis and lymphangiogenesis
Background: Some clinical trials have shown the usefulness of stem cell therapy for diabetic foot ulcers. However, the donor supply is limited, and the process is time consuming and expensive. This study assessed the therapeutic effects of neonatal porcine bone marrow–derived mesenchymal stem cell (npBM‐MSC) xenotransplantation using diabetic wound model mice.Methods: All layers of back skin were removed from streptozotocin‐induced diabetic mice. In the npBM‐MSCs group, npBM‐MSCs were transplanted to the wound, and syngeneic mouse bone marrow–derived mesenchymal stem cells (mBM‐MSCs) were transplanted to the wound in the mBM‐MSCs group. The control group comprised diabetic mice that did not receive cellular therapy. The therapeutic effects of the transplantation were evaluated according to the rate of wound closure and the promotion of neovascularization in the wound.Results: The wound closure rate was significantly improved in the npBM‐MSCs group compared with the control group (p < .001 at postoperative day [POD] 4 and p < .01 at POD 7) and mBM‐MSCs groups (p < .05 at POD 4). Prominent promotion of both angiogenesis and lymphangiogenesis was observed in the npBM‐MSCs group. Furthermore, the expression of murine Prox1 and both porcine and murine Vegfs and Tgfb1 in the wounds was enhanced until POD 4 by npBM‐MSCs transplantation. The amounts of vascular endothelial growth factor (VEGF) A, VEGFC, and transforming growth factor β1 secreted from npBM‐MSCs were higher than those from mBM‐MSCs (p < .05).Conclusion: Xenotransplantation of npBM‐MSCs improved diabetic wound healing by promoting both angiogenesis and lymphangiogenesis.
- 3 November 2021
- Published by Wiley in Xenotransplantation
- Vol. 28 (6) , e12717
Development and characterization of Gal KO porcine bone marrow‐derived mesenchymal stem cells
Background: We demonstrated that neonatal porcine bone marrow‐derived mesenchymal stem cell (npBM‐MSCs) could improve a critical ischemic limb disease in rat model more efficiently compared with human MSCs. However, since porcine MSC presents galactosyl‐alpha 1,3‐galactose antigen (Gal antigen), MSC could be eliminated by the xenogeneic rejection. Recently, we established Gal knockout (KO) pigs by a technique of the electroporation of the CRISPR/Cas9 system into vitro‐fertilized zygotes. In this study, we hypothesized that MSC from the established Gal KO pigs could further improve the efficacy. Before examining the hypothesis, in this study, we have established and characterized bone marrow‐derived MSC from the Gal KO adult pigs (apBM‐MSCs).Methods: Mononuclear cells (MNCs) were isolated from bone marrow cells of both Gal KO adult pigs and wild‐type (WT) adult pigs. MNCs were further manipulated to create Gal KO apBM‐MSCs and WT apBM‐MSCs. Both MSCs were assessed by their surface markers, the capability of differentiation into adipocytes, osteocytes and chondrocytes, grow speed and colony‐forming assay. To assess the efficacy of Gal KO apBM‐MSCs, angiogenesis‐related genes and immunosuppression‐related genes were assessed by cytokine stimulation.Results: Gal KO apBM‐MSC showed no Gal antigen on their cell surfaces. Both Gal KO apBM‐MSCs and WT apBM‐MSCs, presented little or no negative surface markers of MSCs, while they presented positive surface markers of MSCs. Furthermore, Gal KO apBM‐MSCs were able to differentiate into adipocytes, osteocytes, and chondrocytes as well as WT apBM‐MSCs. There was no difference in doubling time between Gal KO apBM‐MSCs and WT apBM‐MSCs. Interestingly, the colony‐forming efficiency of Gal KO apBM‐MSCs was about half that of WT apBM‐MSC. However, angiogenesis and immunosuppression‐related genes were equally upregulated in both Gal KO apBM‐MSCs and WT apBM‐MSCs by cytokine stimulation.Conclusion: We created and characterized Gal KO apBM‐MSCs which showed similar characteristics and cytokine‐induced gene upregulation to the WT apBM‐MSCs.
- 3 November 2021
- Published by Wiley in Xenotransplantation
- Vol. 28 (6) , e12717
Development and characterization of Gal KO porcine bone marrow‐derived mesenchymal stem cells
Background: We demonstrated that neonatal porcine bone marrow‐derived mesenchymal stem cell (npBM‐MSCs) could improve a critical ischemic limb disease in rat model more efficiently compared with human MSCs. However, since porcine MSC presents galactosyl‐alpha 1,3‐galactose antigen (Gal antigen), MSC could be eliminated by the xenogeneic rejection. Recently, we established Gal knockout (KO) pigs by a technique of the electroporation of the CRISPR/Cas9 system into vitro‐fertilized zygotes. In this study, we hypothesized that MSC from the established Gal KO pigs could further improve the efficacy. Before examining the hypothesis, in this study, we have established and characterized bone marrow‐derived MSC from the Gal KO adult pigs (apBM‐MSCs).Methods: Mononuclear cells (MNCs) were isolated from bone marrow cells of both Gal KO adult pigs and wild‐type (WT) adult pigs. MNCs were further manipulated to create Gal KO apBM‐MSCs and WT apBM‐MSCs. Both MSCs were assessed by their surface markers, the capability of differentiation into adipocytes, osteocytes and chondrocytes, grow speed and colony‐forming assay. To assess the efficacy of Gal KO apBM‐MSCs, angiogenesis‐related genes and immunosuppression‐related genes were assessed by cytokine stimulation.Results: Gal KO apBM‐MSC showed no Gal antigen on their cell surfaces. Both Gal KO apBM‐MSCs and WT apBM‐MSCs, presented little or no negative surface markers of MSCs, while they presented positive surface markers of MSCs. Furthermore, Gal KO apBM‐MSCs were able to differentiate into adipocytes, osteocytes, and chondrocytes as well as WT apBM‐MSCs. There was no difference in doubling time between Gal KO apBM‐MSCs and WT apBM‐MSCs. Interestingly, the colony‐forming efficiency of Gal KO apBM‐MSCs was about half that of WT apBM‐MSC. However, angiogenesis and immunosuppression‐related genes were equally upregulated in both Gal KO apBM‐MSCs and WT apBM‐MSCs by cytokine stimulation.Conclusion: We created and characterized Gal KO apBM‐MSCs which showed similar characteristics and cytokine‐induced gene upregulation to the WT apBM‐MSCs.
- 10 August 2021
- Published by Wiley in Journal of Diabetes
- Vol. 13 (11) , 940-942
Efficacy and safety of total pancreatectomy with islet autotransplantation: A clinical study in Japan
- 10 August 2021
- Published by Wiley in Journal of Diabetes
- Vol. 13 (11) , 940-942
Efficacy and safety of total pancreatectomy with islet autotransplantation: A clinical study in Japan